Objective Male breast cancer(MBC) is a rare disease representing less than 1%of all malignancies.The objective of the study is to report clinicopathological characteristics,treatment patterns,and outcomes of MBC in Ma...Objective Male breast cancer(MBC) is a rare disease representing less than 1%of all malignancies.The objective of the study is to report clinicopathological characteristics,treatment patterns,and outcomes of MBC in Mansoura University Hospital,Egypt. Methods This retrospective study focused on male breast cancer patients during 10 years(2000-2009).The studied variables were data regarding general characteristics of patients,treatment modalities and survival. Results The series included 37 patients(0.8%of all breast cancer).The median age was 57.7 years(range:26-86 years).The main clinical complaint was a mass beneath the areola in 94.5%of the cases.Most patients had a locally advanced disease.94.5%of tumors were invasive duct carcinomas.The treatment was essentially surgery in 91.8%,followed by adjuvant radiotherapy(in 89.2%), hormonal therapy(in 56.7%) and chemotherapy(in 91.8%).Follow-up period ranged from 6-115 months.Local recurrence occurred in 4 cases and metastasis in 11 cases.The 2-year and 5-year overall survival(OS) rates were 81.6%and 60.5%,respectively.The 2-year and 5-year disease-free survival(DFS) rates were 68.4%,and 52.6%,respectively.OS was not significantly affected by any of the studied parameters.Factors influencing DFS were:T stage(P=0.05),positive lymph nodes(P=0.043),metastasis(P=0.004),and chemotherapy (P=0.046). Conclusions MBC is a rare disease and often diagnosed at a locally advanced stage.The management of male and female breast carcinoma is identical.Future research for better understanding of this disease is needed to improve the management and prognosis of male breast cancer patients.展开更多
BACKGROUND Metaplastic breast cancer(MBC)is a rare subtype of breast cancer.They constitute less than 1%of breast cancer cases and are much rarer in males.There are few reports of MBC because of its rarity.MBC,an aggr...BACKGROUND Metaplastic breast cancer(MBC)is a rare subtype of breast cancer.They constitute less than 1%of breast cancer cases and are much rarer in males.There are few reports of MBC because of its rarity.MBC,an aggressive type of cancer,is refractory to common treatment modalities of breast cancer and has a poor prognosis.CASE SUMMARY We report a case of MBC in a 78-year-old man.He visited our clinic with a palpable mass on the left breast with no masses in the axillary areas.He had previously undergone robot-assisted laparoscopic radical prostatectomy for prostate cancer,but there was no family history of malignancy.The breast mass was visible on ultrasonography,mammography,and magnetic resonance imaging,and chest computed tomography revealed a lung mass in the posterior basal segment of the right lower lobe.The patient was diagnosed with metaplastic carcinoma on core needle biopsy with lung metastasis.Total mastectomy with sentinel lymph node biopsy and video-assisted segmentectomy of the right lung was performed.However,multiple metastases appeared 3 mo after surgery in the brain,chest,and abdomen,and the patient died 5 mo after the initial diagnosis.CONCLUSION MBC is an aggressive and extremely rare breast cancer type.Further case reports are needed to determine the optimal treatment.展开更多
BACKGROUND Breast cancer(BC)frequency in males is extremely low and tumor features vary from its female counterpart.Breast cancer clinical and pathological features differ by race in women.Tumor infiltrating lymphocyt...BACKGROUND Breast cancer(BC)frequency in males is extremely low and tumor features vary from its female counterpart.Breast cancer clinical and pathological features differ by race in women.Tumor infiltrating lymphocyte(TIL)levels,mismatch repair(MMR)protein loss,androgen receptor(AR)expression,and PIK3CA gene mutations are predictive biomarkers of response to biological therapy in female BC.There is limited information about clinical and pathological features as well as predictive biomarkers in males of non-Caucasian races with BC.AIM To investigate clinicopathological features and biomarkers of BC tumors in males and their prognostic value in Peruvian population.METHODS This study looked at a single-institution series of 54 Peruvian males with invasive BC who were diagnosed from Jan 2004 to June 2018.Standard pathological features,TIL levels,MMR proteins,AR immunohistochemistry staining,and PIK3CA gene mutations were prospectively evaluated in cases with available paraffin material.Percentage of AR and estrogen receptor(ER)positive cells was additionally calculated by software after slide scanning.Statistical analyses included association tests,intraclass correlation test and Kaplan Meier overall survival curves.RESULTS The median age was 63 years and most cases were ER-positive(85.7%),HER2 negative(87.2%),Luminal-A phenotype(60%)and clinical stage II(41.5%)among our male breast tumors.Median TIL was 10%and higher levels tended to be associated with Luminal-B phenotype and higher grade.AR-positive was found in 85.3%and was correlated with ER(intraclass index of 0.835,P<0.001).Loss of MMR proteins was found in 15.4%and PIK3CA mutation(H1047R)in 14.3%(belonged to the Luminal-A phenotype).Loss of MMR proteins was associated with AR-negative(P=0.018)but not with ER(P=0.43)or TIL(P=0.84).Early stages(P<0.001)and lower grade(P=0.006)were associated with longer overall survival.ER status,phenotype,AR status,TIL level,MMR protein loss nor PIK3CA mutation was not associated with survival(P>0.05).CONCLUSION Male BC is usually ER and AR positive,and Luminal-A.MMR loss and PIK3CA mutations are infrequent.Stage and grade predicted overall survival in our South American country population.展开更多
Between 1985 and 1989, 285 cases of metastatic carcinoma in the supraclavicular lymph nodes were treated by the following five methods: Chinese medication, radiotherapy plus Chinese medication, chemotherapy plus Chine...Between 1985 and 1989, 285 cases of metastatic carcinoma in the supraclavicular lymph nodes were treated by the following five methods: Chinese medication, radiotherapy plus Chinese medication, chemotherapy plus Chinese medication, combined Chinese and Western medicine and expectant treatment. Analysis shows that radiotherapy plus Chinese medication has the best curative effect with an effective rate of 75.5%. The effective rates were 74.2% for the combined treatment, 55.5% for the chemotherapy plus medication, 12.5% for the Chinese medication, and none for expectant treatment.展开更多
文摘Objective Male breast cancer(MBC) is a rare disease representing less than 1%of all malignancies.The objective of the study is to report clinicopathological characteristics,treatment patterns,and outcomes of MBC in Mansoura University Hospital,Egypt. Methods This retrospective study focused on male breast cancer patients during 10 years(2000-2009).The studied variables were data regarding general characteristics of patients,treatment modalities and survival. Results The series included 37 patients(0.8%of all breast cancer).The median age was 57.7 years(range:26-86 years).The main clinical complaint was a mass beneath the areola in 94.5%of the cases.Most patients had a locally advanced disease.94.5%of tumors were invasive duct carcinomas.The treatment was essentially surgery in 91.8%,followed by adjuvant radiotherapy(in 89.2%), hormonal therapy(in 56.7%) and chemotherapy(in 91.8%).Follow-up period ranged from 6-115 months.Local recurrence occurred in 4 cases and metastasis in 11 cases.The 2-year and 5-year overall survival(OS) rates were 81.6%and 60.5%,respectively.The 2-year and 5-year disease-free survival(DFS) rates were 68.4%,and 52.6%,respectively.OS was not significantly affected by any of the studied parameters.Factors influencing DFS were:T stage(P=0.05),positive lymph nodes(P=0.043),metastasis(P=0.004),and chemotherapy (P=0.046). Conclusions MBC is a rare disease and often diagnosed at a locally advanced stage.The management of male and female breast carcinoma is identical.Future research for better understanding of this disease is needed to improve the management and prognosis of male breast cancer patients.
基金Supported by the 2020 research grant from Pusan National University Yangsan Hospital,No.2020-193.
文摘BACKGROUND Metaplastic breast cancer(MBC)is a rare subtype of breast cancer.They constitute less than 1%of breast cancer cases and are much rarer in males.There are few reports of MBC because of its rarity.MBC,an aggressive type of cancer,is refractory to common treatment modalities of breast cancer and has a poor prognosis.CASE SUMMARY We report a case of MBC in a 78-year-old man.He visited our clinic with a palpable mass on the left breast with no masses in the axillary areas.He had previously undergone robot-assisted laparoscopic radical prostatectomy for prostate cancer,but there was no family history of malignancy.The breast mass was visible on ultrasonography,mammography,and magnetic resonance imaging,and chest computed tomography revealed a lung mass in the posterior basal segment of the right lower lobe.The patient was diagnosed with metaplastic carcinoma on core needle biopsy with lung metastasis.Total mastectomy with sentinel lymph node biopsy and video-assisted segmentectomy of the right lung was performed.However,multiple metastases appeared 3 mo after surgery in the brain,chest,and abdomen,and the patient died 5 mo after the initial diagnosis.CONCLUSION MBC is an aggressive and extremely rare breast cancer type.Further case reports are needed to determine the optimal treatment.
基金the Consejo Nacional de Ciencia,Tecnologia e Innovacion Tecnologica,No.198-2015-FONDECYT.
文摘BACKGROUND Breast cancer(BC)frequency in males is extremely low and tumor features vary from its female counterpart.Breast cancer clinical and pathological features differ by race in women.Tumor infiltrating lymphocyte(TIL)levels,mismatch repair(MMR)protein loss,androgen receptor(AR)expression,and PIK3CA gene mutations are predictive biomarkers of response to biological therapy in female BC.There is limited information about clinical and pathological features as well as predictive biomarkers in males of non-Caucasian races with BC.AIM To investigate clinicopathological features and biomarkers of BC tumors in males and their prognostic value in Peruvian population.METHODS This study looked at a single-institution series of 54 Peruvian males with invasive BC who were diagnosed from Jan 2004 to June 2018.Standard pathological features,TIL levels,MMR proteins,AR immunohistochemistry staining,and PIK3CA gene mutations were prospectively evaluated in cases with available paraffin material.Percentage of AR and estrogen receptor(ER)positive cells was additionally calculated by software after slide scanning.Statistical analyses included association tests,intraclass correlation test and Kaplan Meier overall survival curves.RESULTS The median age was 63 years and most cases were ER-positive(85.7%),HER2 negative(87.2%),Luminal-A phenotype(60%)and clinical stage II(41.5%)among our male breast tumors.Median TIL was 10%and higher levels tended to be associated with Luminal-B phenotype and higher grade.AR-positive was found in 85.3%and was correlated with ER(intraclass index of 0.835,P<0.001).Loss of MMR proteins was found in 15.4%and PIK3CA mutation(H1047R)in 14.3%(belonged to the Luminal-A phenotype).Loss of MMR proteins was associated with AR-negative(P=0.018)but not with ER(P=0.43)or TIL(P=0.84).Early stages(P<0.001)and lower grade(P=0.006)were associated with longer overall survival.ER status,phenotype,AR status,TIL level,MMR protein loss nor PIK3CA mutation was not associated with survival(P>0.05).CONCLUSION Male BC is usually ER and AR positive,and Luminal-A.MMR loss and PIK3CA mutations are infrequent.Stage and grade predicted overall survival in our South American country population.
文摘Between 1985 and 1989, 285 cases of metastatic carcinoma in the supraclavicular lymph nodes were treated by the following five methods: Chinese medication, radiotherapy plus Chinese medication, chemotherapy plus Chinese medication, combined Chinese and Western medicine and expectant treatment. Analysis shows that radiotherapy plus Chinese medication has the best curative effect with an effective rate of 75.5%. The effective rates were 74.2% for the combined treatment, 55.5% for the chemotherapy plus medication, 12.5% for the Chinese medication, and none for expectant treatment.
